Stoke Therapeutics grants 245,920 options on Stoke Therapeutics stock
Published on 10/18/2026 at 12:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical milestones and dates
- Stoke Therapeutics granted 245,920 stock options on October 16, 2026.
- Second-quarter 2026 revenue reached USD 9.33 million.
- Eight OSPREY trial sites were active by October 12, 2026.
Stoke Therapeutics (ISIN US86150R1077) granted 245,920 stock options to 18 new employees on October 16, 2026, including 70,000 options for newly appointed Chief Information Officer Stephen Aschettino. The grants add an employee-compensation event to a month already marked by clinical updates.
245,920 options join the clinical story
According to FinancialContent on October 16, 2026, the options carried an exercise price of USD 24.61 and will vest over four years. The 10-year options were granted under Stoke's 2023 Inducement Plan.
Three dated company steps
On October 6, 2026, Stoke Therapeutics said the first two OSPREY dose cohorts for STK-002 were complete. On October 12, the company presented STK-002 data and said all eight planned OSPREY clinical trial sites were active. On October 16, it announced 245,920 options for 18 new employees, according to FinancialContent.
What comes next for clinical timing?
The third OSPREY cohort is expected to complete by the end of 2026, while initial safety and efficacy data from later cohorts are anticipated in the first half of 2027. The next scheduled reporting date is November 3, 2026, when Stoke is estimated to discuss third-quarter results after the market closes, according to MarketBeat.
Revenue and valuation set the backdrop
Stoke reported USD 9.33 million in revenue for the second quarter of 2026, compared with USD 4.89 million expected, while diluted earnings per share were minus USD 0.93 versus a consensus estimate of minus USD 0.82. As of October 16, 2026, the company had a USD 1.6 billion market capitalization and a Nasdaq price of USD 24.17 at 4:00 p.m. ET; its 52-week range was USD 20.32 to USD 40.22.
The further course of trading is shown by the continuously updated real-time quote of Stoke Therapeutics stock.
Stoke Therapeutics stock key facts
- Company: Stoke Therapeutics, Inc.
- ISIN: US86150R1077
- Ticker: STOK
- Primary exchange: Nasdaq
- Market capitalization: USD 1.6 billion (as of October 16, 2026)
- 52-week range: USD 20.32-USD 40.22 (as of October 16, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
